S-1/A: Envoy Medical Amends S-1, Details Clinical Progress & Financial Hurdles

Envoy Medical, a hearing health company, filed an S-1/A registration statement to allow selling stockholders to resell up to 15.1 million shares, while detailing ongoing clinical trials for its Acclaim CI, significant financial losses, and Nasdaq compliance challenges.

Summary

• Envoy Medical is focused on developing innovative medical technologies for hearing loss, with its lead product candidate being the fully implanted Acclaim Cochlear Implant (Acclaim CI).
• The Acclaim CI received FDA Breakthrough Device Designation in 2019 and has advanced to the second and final stage of its pivotal clinical trial, with 10 patients successfully completing their 3-month follow-up with no serious adverse events.
• The second stage of the clinical trial will enroll an additional 46 patients, bringing the total study population to 56, with data collection and analysis expected after all 12-month follow-up visits.
• The company anticipates obtaining FDA approval for the Acclaim CI's Premarket Approval (PMA) application in the second half of 2027 or first half of 2028, depending on the FDA's review process.
• Envoy Medical reported net losses of $6.5 million for the three months ended September 30, 2025, and $17.2 million for the nine months ended September 30, 2025.
• The accumulated deficit stood at $305.7 million as of September 30, 2025.
• The company raised approximately $2.5 million in gross proceeds from a September 2025 registered direct offering and an additional $4.0 million from an October 2025 registered direct offering.
• Potential additional gross proceeds of approximately $7.5 million and $12.0 million could be received if warrants from the September and October private placements, respectively, are exercised for cash.
• Envoy Medical is not in compliance with Nasdaq's $35 million market value of listed securities requirement and has been granted an exception until February 23, 2026.
• The company also received a Nasdaq notice for failing to comply with the $1.00 minimum bid price requirement, with an initial compliance period until May 18, 2026.
• Material weaknesses in internal control over financial reporting were identified for the years ended December 31, 2024 and 2023, including insufficient accounting personnel, lack of formal risk assessment, and inadequate controls over significant accounts and IT general controls.
• The company's financial statements contain an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern.
• The Esteem Fully Implanted Active Middle Ear Implant (Esteem FI-AMEI), FDA-approved in 2010, failed to gain commercial traction primarily due to a lack of reimbursement, though a new bipartisan Congressional bill in February 2024 seeks to reclassify it for Medicare/Medicaid coverage.
• The company's business plan relies on certain assumptions about the market for its product, with an estimated 2.8 million adults in the U.S. potentially qualifying for a cochlear implant, representing a market opportunity of over $80 billion.
• A lawsuit was filed in November 2023 by Atlas Merchant Capital SPAC Fund I LP against the company and former officers, alleging improper prevention of share redemption and seeking approximately $9.4 million in damages.

Sentiment

Score: 3

Explanation: The company faces significant financial distress, including substantial net losses, a large accumulated deficit, and a going concern warning. Nasdaq compliance issues pose an immediate delisting risk. While the Acclaim CI clinical trial progress and Breakthrough Device Designation are positive, the commercialization timeline is uncertain, and the company relies heavily on future capital raises, which may not be available on favorable terms. The identified product defect in the EFS adds further uncertainty.

Positives

• The Acclaim CI received FDA Breakthrough Device Designation in 2019, which may expedite its development and review process.
• The pivotal clinical trial for the Acclaim CI has successfully advanced to its second and final stage, with initial 3-month data from 10 patients showing no serious adverse events and device effectiveness.
• The Acclaim CI's fully implanted design offers potential advantages over traditional partially implanted devices, including increased daily usage, hearing at night and in water, reduced battery maintenance, and lower stigma.
• The company successfully raised approximately $6.5 million in gross proceeds from September and October 2025 registered direct offerings.
• Potential for an additional $19.5 million in gross proceeds if all warrants from the September and October private placements are exercised for cash.
• The Nasdaq Hearings Panel granted an exception for compliance with the $35 million market value of listed securities requirement through February 23, 2026.
• A bipartisan Congressional bill introduced in February 2024 seeks to reclassify the Esteem FI-AMEI as a prosthetic, potentially enabling Medicare and Medicaid reimbursement and revitalizing the product's commercial viability.
• The company's sensor technology has over two decades of experience from the Esteem FI-AMEI clinical trials, proving a viable and robust alternative to external or implanted microphones.

Negatives

• Reported net losses of $6.5 million for the three months ended September 30, 2025, and $17.2 million for the nine months ended September 30, 2025, indicating continued unprofitability.
• Accumulated deficit of $305.7 million as of September 30, 2025, highlights significant historical losses.
• The company's financial statements include an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern.
• Non-compliance with Nasdaq's $35 million market value of listed securities requirement and the $1.00 minimum bid price requirement, posing a risk of delisting.
• Reliance on future equity offerings, debt financings, or other capital sources to fund operations, with no guarantee of availability on acceptable terms.
• Identified material weaknesses in internal control over financial reporting, including insufficient accounting personnel and lack of formal risk assessment, which could lead to inaccurate financial reporting.
• The Esteem FI-AMEI, despite FDA approval in 2010, failed to gain commercial traction due to lack of reimbursement, demonstrating past commercialization challenges.
• The Acclaim CI's Early Feasibility Study identified a 'signal to noise' issue, introducing unintended noise into the signal path, which requires mitigation and resolution strategies.
• The market price of the Class A Common Stock has been extremely volatile, trading as low as $0.75 and as high as $11.46, and the public float is very illiquid.
• The company will not receive any proceeds from the resale of shares by selling stockholders in this offering, only from warrant exercises.

Risks

• The market price of Class A Common Stock has been and may continue to be extremely volatile, potentially causing substantial losses for investors.
• The public float of Class A Common Stock is very illiquid, and significant sales of newly registered shares could negatively impact the price.
• Exercise of outstanding Public Warrants and other warrants will increase the number of shares eligible for future resale, resulting in dilution to stockholders.
• No intention to pay dividends on Class A Common Stock for the foreseeable future, requiring investors to sell shares for cash flow.
• Lack of analyst coverage could lead to decreased demand and lower stock price/trading volume.
• Future equity offerings could cause further dilution and adversely affect existing stockholders' rights.
• Potential for securities litigation, which is expensive and could divert management attention.
• Failure to meet Nasdaq's continued listing requirements could result in delisting of Class A Common Stock.
• As an early-stage company with a history of losses, profitability in the future is uncertain.
• The Acclaim CI may contain design or manufacturing defects, harming business and financial results.
• Need to raise substantial additional funding, which may not be available on acceptable terms or at all, potentially curtailing product development.
• Failure of key information technology systems, processes, or sites could adversely affect business, including from cyberattacks.
• Unfavorable global economic conditions (geopolitical events, inflation, interest rates) could adversely affect business and ability to raise capital.
• Identified material weaknesses in internal control over financial reporting could lead to inaccurate financial reporting and adversely affect investor confidence.
• The financial statements contain an explanatory paragraph regarding substantial doubt about the ability to continue as a going concern.
• Clinical failure can occur at any stage of clinical development, and current clinical experience may not predict future results.
• Successful commercialization of Acclaim CI depends on obtaining adequate reimbursement levels and favorable pricing policies, which are uncertain.
• Operating in a very competitive business environment with larger, more diversified medical device companies.
• Dependence on third parties to manage pre-clinical studies and clinical trials, leading to potential costs and delays beyond control.
• High dependence on key members of the executive management team; inability to retain them could impede business plans.
• Management team has limited experience managing a public company, potentially diverting attention from day-to-day business.
• Inability to obtain significant patent protection or adequately protect intellectual property rights could limit market share and profitability.
• Patent terms may not be sufficient to effectively protect products for an adequate period.
• Inability to enforce intellectual property rights throughout the world due to varying foreign laws.
• Potential for claims of misappropriation of third-party intellectual property or challenges to ownership of intellectual property.
• Certain directors and/or officers may have interests different from holders of Class A Common Stock due to significant holdings or employment.

Future Outlook

The company expects to continue incurring net losses for the foreseeable future, with increasing research and development, sales and marketing, general and administrative expenses, and capital expenditures. It anticipates obtaining FDA approval for the Acclaim CI's Premarket Approval application in the second half of 2027 or first half of 2028, but this timeline is uncertain and not guaranteed. Substantial additional capital will be required to commercialize the Acclaim CI and fund ongoing operations, with current cash expected to last through February or March 2026 without further warrant exercises or capital raises.

Management Comments

• Management believes the Acclaim CI is a first-of-its-kind cochlear implant with the opportunity to disrupt the existing market.
• Management is confident that the Acclaim CI will be eligible for reimbursement, unlike the Esteem FI-AMEI.
• Management believes that the initial results of the Acclaim CI Early Feasibility Study were primarily promising, despite identifying a signal to noise issue.
• Management believes the fully implanted nature of the Acclaim CI will facilitate increased daily usage and offer other important advantages over alternative hearing loss treatments.
• Management believes strong relationships can be built with both surgical teams and audiologists to ensure understanding and adoption of the Acclaim CI.
• Management views pursuing the commercialization of the Acclaim CI as the appropriate focus and best use of resources, over significant upgrades to the Esteem FI-AMEI.
• Management believes that its existing cash balances combined with future capital raises through debt and equity and cash receipts from product sales will be sufficient to fund ongoing operations through at least one year from the date the unaudited condensed consolidated financial statements are issued.

Industry Context

The company operates in the hearing health and medical device industry, specifically targeting severe to profound sensorineural hearing loss. The cochlear implant market is established with existing market acceptance and reimbursement pathways, currently dominated by major players like Cochlear Ltd., Sonova, and Med-El. Industry trends include a focus on usability, connectivity, lifestyle, miniaturization, and loosening clinical candidacy requirements. The company aims to disrupt this market with its fully implanted Acclaim CI, which leverages the natural ear for sound capture, differentiating it from traditional partially implanted devices that use external microphones.

Comparison to Industry Standards

• The Acclaim CI is positioned as a 'first-of-its-kind' fully implanted cochlear implant, aiming to disrupt a market currently dominated by partially implanted devices from competitors like Cochlear Ltd., Advanced Bionics (Sonova), and Med-El.
• The Esteem FI-AMEI is noted as the 'only FDA approved fully implanted hearing device in the US market,' highlighting its unique regulatory status compared to other hearing devices.
• The Acclaim CI's fully implanted technology, leveraging the natural ear instead of an artificial microphone, is a key differentiator from existing cochlear implants.
• The company believes its Acclaim CI can offer advantages over traditional cochlear implants, such as increased daily usage (24-hours a day), hearing at night and in water, lowered battery maintenance (several days between wireless charges), and no need for backup processors, addressing limitations of competitors' external components.
• The company estimates a 5-8% penetration rate for cochlear implants in the adult population, suggesting a significant unserved market that its fully implanted device could capture, potentially increasing market share beyond what established competitors have achieved.
• The company anticipates the Acclaim CI will demand a higher average selling price than existing partially implanted cochlear implants, which are assumed to be around $30,000.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit was filed on November 14, 2023, by Atlas Merchant Capital SPAC Fund I LP against the company, Whitney Haring-Smith (former CEO), Daniel Hirsch (former CFO), and Anzu SPAC GP I LLC in the Delaware Court of Chancery.
• Atlas alleges it was improperly prevented from redeeming its shares of common stock and that defendants breached the company's organizational documents and fiduciary duties.
• Atlas asserts damages of approximately $9.4 million, plus preand post-judgment interest, costs, and reasonable attorneys' fees.
• The company believes the lawsuit is meritless and is vigorously defending the matter.
• On March 3, 2025, the court partially granted a motion to dismiss, narrowing the scope of the litigation.

Related Party Transactions

• The company issued February 2024, August 2024, and March 2025 Term Loan promissory notes to GAT Funding, LLC, an entity controlled by Glen A. Taylor (a former director and controlling stockholder). These loans totaled $30 million in principal.
• The Term Loans were extinguished on August 25, 2025, in exchange for a one-time payment of $100,000 by the company to GAT, resulting in a $27.879 million gain on extinguishment recorded as a capital contribution.
• The company leases its headquarters office space in Minnesota from Taylor Corporation, an entity controlled by Glen Taylor, with payments totaling $180,000 in 2024.
• The company has a shared services arrangement with Taylor Technology Services, Inc., indirectly owned by Glen Taylor, expensing less than $100,000 in each of the nine months ended September 30, 2025, and 2024.
• A Consulting Agreement was entered into with Oasis Business Consulting, LLC, an entity wholly owned by Robert Potashnick (Interim CFO), for his services, recognizing an expense of $95,000 for the nine months ended September 30, 2025.
• A Voting and Warrant Extension Agreement was entered into on September 4, 2025, with GAT, Taylor Sports Group, Inc. (controlled by Glen A. Taylor), and Glen A. Taylor, extending the exercise term of Term Loan Warrants to December 31, 2028, in exchange for voting agreements on Nasdaq compliance proposals.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from the resale of 15.1 million shares by selling stockholders and potential future equity offerings. The volatile stock price and Nasdaq delisting risk could lead to substantial losses. No cash dividends are expected on Class A Common Stock in the foreseeable future. The lawsuit by Atlas Merchant Capital could result in material damages or other penalties.
• **Employees:** The company expects to hire additional personnel, particularly in R&D, sales, and marketing, to support growth and commercialization efforts. Stock-based compensation is a component of executive compensation, aligning interests with stockholders.
• **Customers (Patients):** The Acclaim CI aims to provide innovative solutions for severe to profound hearing loss, potentially offering improved quality of life and daily usage compared to existing devices. However, product defects or regulatory delays could impact availability and safety.
• **Suppliers:** The company relies on third-party suppliers for critical sub-assemblies and components, making it vulnerable to supply shortages, increased costs, and quality issues, which could affect product development and commercialization.
• **Creditors:** The company's going concern doubt and reliance on future financing indicate elevated credit risk. The extinguishment of term loans from a related party for a nominal payment suggests a favorable outcome for the company but highlights its financial fragility.

Next Steps

• Continue enrollment of 46 additional patients in the second stage of the Acclaim CI pivotal clinical trial.
• Collect and analyze data from all 56 patients after their 12-month follow-up visits.
• Submit a Premarket Approval (PMA) application to the FDA for the Acclaim CI.
• Address and remediate identified material weaknesses in internal control over financial reporting.
• Actively monitor and implement strategies to regain compliance with Nasdaq's $35 million market value of listed securities requirement by February 23, 2026.
• Regain compliance with Nasdaq's $1.00 minimum bid price requirement by May 18, 2026, potentially through a reverse stock split if necessary.
• Seek additional regulatory and marketing approvals for the Acclaim CI in jurisdictions outside the United States, starting with the CE Mark in the European Union.
• Establish a sales, marketing, and distribution infrastructure to commercialize the Acclaim CI upon FDA approval.
• Identify, assess, acquire, license, and/or develop other product candidates and subsequent generations of the current product candidate.
• Maintain, protect, and expand the intellectual property portfolio.
• Identify, hire, and retain additional skilled personnel.
• Create additional infrastructure to support operations as a public company and product development/commercialization efforts.
• Continue efforts to pursue positive reimbursement changes for fully implanted active middle ear implants, potentially benefiting the Esteem FI-AMEI.

Key Dates

Recommendation

Envoy Medical faces severe financial challenges, including substantial and increasing net losses, a significant accumulated deficit, and an explicit 'going concern' warning from its auditors. The company is non-compliant with multiple Nasdaq listing rules, including market value and minimum bid price, leading to a high risk of delisting. While the Acclaim CI has FDA Breakthrough Device Designation and is progressing in clinical trials, commercialization is years away (late 2027/early 2028) and subject to significant regulatory and market uncertainties, including a noted 'signal to noise' defect in early studies. The company's liquidity is precarious, with current cash expected to last only through early 2026 without further capital raises. The recent capital raises, while providing some funds, also involve substantial warrant issuance, leading to significant potential dilution. The stock's extreme volatility and illiquid public float further exacerbate investment risk. Given the profound financial instability, regulatory compliance issues, and long, uncertain path to profitability, the stock presents an exceptionally high-risk profile with a strong likelihood of further value erosion.

Keywords

Hearing Health, Cochlear Implant, Medical Device, FDA Approval, Acclaim CI, Esteem FI-AMEI, SEC Filing, Nasdaq Listing, Clinical Trials, Biotechnology, Healthcare Technology, Capital Raise, Warrants, Financial Losses, Corporate Governance, Intellectual Property